Yazar "Tural, Deniz" için listeleme
-
Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Artaç, Mehmet; Özhan, Nail; Akar, Emre; Çakar, Burcu; Köstek, Osman; Ekenel, Meltem; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Erman, Mustafa (Lippincott Williams & Wilkins, 2021)Background: In the current study, we evaluated whether the response first-line chemotherapy could impact atezolizumab benefit in terms of response rate and overall survival in patients with metastatic urothelial carcinoma. ... -
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Artaç, Mehmet; Özhan, Nail; Akar, Emre; Çakar, Burcu; Köstek, Osman; Paksoy, Nail; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Kılıçkap, Saadettin (American Society of Clinical Oncology, 2020)... -
Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Artaç, Mehmet; Özhan, Nail; Akar, Emre; Çakar, Burcu; Köstek, Osman; Ekenel, Meltem; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy Türköz, Fatma; Oruç, Kerem; Bayram, Selami; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Paksoy, Nail; Dirican, Ahmet; Erdem, Dilek; Selam, Meltem; Tanrıverdi, Özgür; Paydaş, Semra; Urakçı, Zuhat; Atağ, Elif; Güncan, Sabri; Ürün, Yüksel; Alkan, Ali; Kaya, Ali Osman; Tataroğlu Özyükseler, Deniz; Taşkaynatan, Halil; Yıldırım, Mustafa; Sönmez, Müge; Başoğlu, Tuğba; Gündüz, Şeyda; Kılıçkap, Saadettin (Elsevier, 2021)Background: Atezolizumab (ATZ) has demonstrated antitumor activity and manageable safety in previous studies in patients with locally advanced or metastatic platinum resistant urothelial carcinoma. Objective: To compare ... -
Comparison of objective response rate and long-term overall survival in patients with treated immune checkpoint inhibitors in metastatic urothelial carcinoma.
Tural, Deniz; Arslan, Çağatay; Selçukbiricik, Fatih; Ölmez, Ömer Fatih; Akar, Emre; Erman, Mustafa; Ürün, Yüksel; Erdem, Dilek; Kılıçkap, Saadettin (Lippincott Williams & Wilkins, 2023)... -
Crizotinib efficacy in alk-positive advanced stage non-small cell lung cancer patients: A real-world experience from Turkey
Kılıçkap, Sadettin; Öztürk, Akın; Karadurmuş, Nuri; Korkmaz, Taner; Yumuk, Perran Fulden; Çiçin, İrfan; Paydaş, Semra; Çılbır, Ebru; Sakalar, Teoman; Uysal, Mükremin; Üskent, Necdet; Demir, Nurcan; Sakin, Ayşegül; Turhal, Nazım Serdar; Keskin, Serhat; Tural, Deniz; Eralp, Yeşim; Buğdaycı Başal, Fatma; Yaşar, Hatime Arzu; Sendur, Mehmet Ali Nahit; Demirci, Umut; Çubukçu, Erdem; Karaağaç, Mustafa; Karaca, Saziye; Tatlı, Ali Murat; Yetişyiğit, Tarkan; Urvay, Semiha; Gürsoy, Pınar; Oyan Uluç, Başak; Turna, Zeynep Hande; Küçüköner, Mehmet; Ölmez, Ömer Fatih; Çabuk, Devrim; Şeker, Mesut; Ünal, Olçun Umut; Meydan, Nezih; Okutur, Sadi Kerem; Tunalı, Duygu (Elsevier Science Inc, 2018)Background: Increasing evidence leads to a ratiocination that genetic heterogeneity of the lung adenocarcinoma patients with sensitive EGFR mutations may impact clinical responses and outcomes to EGFR-TKIs. Method: We ... -
The efficacy and safety analysis of the treatments of everolimus and exemestane combination in 101 metastatic breast cancer patients: Real-life experience from Turkey
Bilici, Abdullah Yasin; Menekşe, Serkan; Akın, Şeyma Selin; Değirmenci, Mehmet Fatih Kağan; Ölmez, Ömer Fatih; Avcı, Nilüfer; Sakalar, Teoman; Tural, Deniz; Kaplan, Muhammet Ali; Tanrıverdi, Özgür; Bilgetekin, İrem; Uslu, Rabiye (Amer Assoc Cancer Research, 2019)Background: Endocrine treatment and chemotherapy are a treatment options for patients with hormone receptor (HR) positive and HER2-negative metastatic breast cancer (MBC). However, response to first-line hormone treatment ... -
Elevation in serum uric acid levels predicts favourable response to erlotinib treatment in patients with metastatic non-small-cell lung cancer
Selçukbiricik, Fatih; Özdoğan, Elif; Dağel, Tuncay; Tanju, Serhan; Erus, Suat; Ertuğrul, Lale Aslıhan; Kapdağlı, Murat; Tural, Deniz; Bilici, Ahmet; Dilege, Şükrü; Mendel, Nil Molinas; Kanbay, Mehmet (Wiley, 2020)What is known and objective Erlotinib is a small molecule tyrosine kinase inhibitor which blocks the activation of epidermal growth factor receptor (EGFR), a transmembrane receptor that is upregulated in many cancer types. ... -
Five-year outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice
Tural, Deniz; Arslan, Çağatay; Selçukbiricik, Fatih; Ölmez, Ömer Fatih; Akar, Emre; Erman, Mustafa; Ürün, Yüksel; Erdem, Dilek; Karadurmuş, Nuri; Kılıçkap, Saadettin (CIG Media Group, 2023)This 5-year analysis of real-world data confirms the durable response and long-term survival with ICTs in a broader range of patients with metastatic urothelial carcinoma. After 24 months, PFS and OS curves remained nearly ... -
Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients
Peled, Nir; Gillis, Roni; Kılıçkap, Saadettin; Froesch, Patrizia; Orlov, Sergei; Filippova, Elena; Demirci, Umut; Christopoulos, Petros; Çiçin, İrfan; Buğdaycı Basal, Fatma; Yılmaz, Cengiz; Fedor, Moiseenko; Korkmaz, Taner; Paydaş, Semra; Gautschi, Oliver; Zırtıloğlu, Alişan; Eralp, Yeşim; Yeşil Çınkır, Havva; Sezer, Ahmet; Erman, Mustafa; Tural, Deniz; Turna, Hande; Mazieres, Julien; Dudnik, Elizabeth; Reguart, Noemi; Camidge, David Ross; Ng, Terry L.; Çay Şenler, Filiz; Beypınar, İsmail; Yazılıtaş, Doğan; Demirkazık, Ahmet; Karaoğlu, Aziz; Okutur, Kerem; Coşkun, Hasan Şenol; Şendur, Mehmet Ali Nahit; Işıkdoğan, Abdurrahman; Çabuk, Devrim; Yumuk, Perran Fulden; Yıldız, İbrahim; Kaplan, Mehmet Ali; Özyılkan, Özgür; Öztop, İlhan; Ölmez, Ömer Fatih; Aydın, Kübra; Aydıner, Adnan; Meydan, Nezih; Grinberg, Roxana Denisa; Roisman, Laila C. (Elsevier Science Inc, 2021)Introduction: Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1(+) is still pending. ... -
Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients
Peled, Nir; Gillis, Roni; Kılıçkap, Saadettin; Froesch, Patrizia; Orlov, Sergei; Filippova, Elena; Demirci, Umut; Christopoulos, Petros; Çiçin, İrfan; Buğdaycı Basal, Fatma; Yılmaz, Cengiz; Fedor, Moiseenko; Korkmaz, Taner; Paydaş, Semra; Gautschi, Oliver; Zırtıloğlu, Alişan; Eralp, Yeşim; Yeşil Çınkır, Havva; Sezer, Ahmet; Erman, Mustafa; Tural, Deniz; Turna, Hande; Mazieres, Julien; Dudnik, Elizabeth; Reguart, Noemi; Camidge, David Ross; Ng, Terry L.; Çay Şenler, Filiz; Beypınar, İsmail; Yazılıtaş, Doğan; Demirkazık, Ahmet; Karaoğlu, Aziz; Okutur, Kerem; Coşkun, Hasan Şenol; Şendur, Mehmet Ali Nahit; Işıkdoğan, Abdurrahman; Çabuk, Devrim; Yumuk, Perran Fulden; Yıldız, İbrahim; Kaplan, Mehmet Ali; Özyılkan, Özgür; Öztop, İlhan; Ölmez, Ömer Fatih; Aydın, Kübra; Aydıner, Adnan; Meydan, Nezih; Grinberg, Roxana Denisa; Roisman, Laila C. (Elsevier Ireland Ltd, 2020)Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we ... -
Late relapse of testicular cancer: Recurrence after 24 years and treatment with chemotherapy alone
Akar, Emre; Tural, Deniz; Arslan, Deniz; Başsorgun, Cumhur İbrahim; Yıldız, Özcan (Medknow Publications, 2015)Late relapse of testicular cancer, defined as >2 years interval between initial treatment and recurrence, is a rare disease with the incidence rate of 2.6%. Due to its chemoresistant features, treatment options of late ... -
Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice
Tural, Deniz; Arslan, Çağatay; Selçukbiricik, Fatih; Ölmez, Ömer Fatih; Erman, Mustafa; Ürün, Yüksel; Karadurmuş, Nuri; Akar, Emre; Kılıçkap, Saadettin (Lippincott Williams & Wilkins, 2022)Background: Anti-tumor activity and manageable safety profile of immune checkpoint blockade therapies (ICT) have been demonstrated in previous clinical trials in patients with metastatic urothelial carcinoma. To the best ... -
Lorlatinib in ALK- or ROS1-positive non-small cell lung cancer patients: Experience from an early access program in Turkey
Kılıçkap, Saadettin; Demirci, Umut; Buğdaycı, Fatma; Tural, Deniz; Korkmaz, Taner; Paydaş, Semra; Yılmaz, Coşkun; Tuna, Hande; Sezer, Ahmet; Yeşil Çinkir, Havva; Erman, Münire; Eralp, Yeşim; Çabuk, Devrim; Işıkdoğan, Abdurrahman; Demirkazık, Ahmet; Karaoğlu, Aziz; Yazılıtaş, Doğan; Çay Şenler, Filiz; Yumuk, Perran Fulden; Coşkun, Hatice; Yıldız, İbrahim; Öztop, İlhan; Beypınar, İsmail; Aydın, Kübra; Kaplan, M.; Meydan, Nezih; Ölmez, Ömer Fatih; Seber, Samile; Arslan, Çağatay; Şendur, Mehmet Ali Nahit; Çiçin, İrfan (Elsevier Science, 2019)Background: Lorlatinib, a third generation ALK and ROS1 inhibitor, is indicated for the treatment of patients with ALK+ metastatic NSCLC whose disease has progressed on crizotinib and at least one second-generation ALK ... -
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
Kılıçkap, Saadettin; Öztürk, Akın; Karadurmuş, Nuri; Korkmaz, Taner; Yumuk, Perran Fulden; Çiçin, İrfan; Paydaş, Semra; Çılbır, Ebru; Şakalar, Teoman; Uysal, Mükremin; Yeşil Çınkır, Havva; Üskent, Necdet; Demir, Necla; Sakin, Abdullah; Dursun, Oldaç Uras; Aver, Birkan; Turhal, Nazım Serdar; Keskin, Serkan; Tural, Deniz; Eralp, Yeşim; Buğdaycı Başal, Fatma; Yaşar, Hatime Arzu; Şendur, Mehmet Ali Nahit; Demirci, Umut; Çubukçu, Erdem; Karaağaç, Mustafa; Çakar, Burcu; Tatlı, Ali Murat; Yetişyiğit, Tarkan; Urvay, Semiha; Gürsoy, Pınar; Oyan, Başak; Turna, Zeynep Hande; Işıkdoğan, Abdurrahman; Ölmez, Ömer Fatih; Yazıcı, Ozan; Çabuk, Devrim; Şeker, Mehmet Metin; Ünal, Olçun Ümit; Meydan, Nezih; Okutur, Sadi Kerem; Tunalı, Didem; Erman, Mustafa (2024)To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, ... -
The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b
Mutlu, Hasan; Gündüz, Şeyda; Büyükçelik, Abdullah; Yıldız, Özcan; Uysal, Mükremin; Tural, Deniz; Bozcuk, Hakan; Çoşkun, Hasan Şenol (CIG Media Group, 2014)The effects of cytoreductive nephrectomy (CRN) on prognosis of patients with metastatic renal cell cancer (RCC) using antiangiogenic targeted agents were evaluated. The median overall survival was significantly higher in ... -
PET-CT changes the management and improves outcome in patients with recurrent colorectal cancer
Tural, Deniz; Selçukbiricik, Fatih; Sağer, Sait; Akar, Emre; Yıldız, Özcan; Serdengeçti, Süheyla (Medknow Publications, 2014)Background: The present study aims to analyze the impact of positron emission tomography/computed tomography (PET/CT) on management change in patients with suspected or proven colorectal cancer recurrence, and to assess ... -
Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer
Gündüz, Şeyda Gülenay; Mutlu, Hasan; Tural, Deniz; Yıldız, Özcan; Uysal, Mükremin; Çoşkun, Hasan Şenol; Bozcuk, Hakan Şat (Wiley-Blackwell, 2015)Aim: The objective of this study was to evaluate the blood platelet-lymphocyte ratio (PLR) for its prognostic value in patients with metastatic renal cell cancer (RCC). Methods: We retrospectively reviewed 100 patients ... -
Preoperative versus postoperative chemoradiotherapy in stage T3, N0 rectal cancer
Tural, Deniz; Selçukbiricik, Fatih; Yıldız, Özcan; Elçin, Olgun; Erdamar, Sibel; Güney, Sabri; Demireli, Fuat; Büyükünal, Evin; Serdengeçti, Süheyla (Springer, 2014)The study populations of previous preoperative chemoradiotherapy (pre-CRT) studies have consisted of mixed clinical stages, such as cT3-cT4 and/or cN positive. For this reason, it has not been possible to demonstrate whether ... -
Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy
Yıldız, İbrahim; Bilici, Ahmet; Karadurmuş, Nuri; Özer, Leyla; Tural, Deniz; Kaplan, Mehmet Ali; Akman, Tülay; Bayoğlu, İbrahim Vedat; Uysal, Mükremin; Yıldız, Yaşar; Tanrıverdi, Özgür; Yazıcı, Ozan; Sürmeli, Zeki; Turhal, Nazim Serdar; Bavbek, Sevil; Selçukbiricik, Fatih; Koca, Doğan; Başaran, Mert (Sage Publications Ltd, 2018)Background: The primary objective of our study was to examine the clinical outcomes and prognosis of patients with metastatic renal cell carcinoma (mRCC) with brain metastases (BMs) receiving targeted therapy. Patients and ... -
Prognostic factors in patients with metastatic urothelial carcinoma who have been treated with atezolizumab
Tural, Deniz; Ölmez, Ömer Fatih; Sümbül, Ahmet Taner; Özhan, Nail; Akar, Ebru; Çakar, Bilge; Köstek, Osman; Ekenel, Mahmut; Erman, Mustafa; Coşkun, Hasan Şenol; Selçukbiricik, Fatih; Keskin, Özge; Paksoy, Fatma; Oruç, Korkmaz; Bayram, Süleyman Nuri; Yılmaz, Uğur; Bilgetekin, İrem; Yıldız, Birol; Şendur, Mehmet Ali Nahit; Artaç, Macide (Elsevier, 2020)Background: In the current study, we evaluated pretreatment prognostic factors foroverall survival (OS) in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy in the Expanded-Access ...